# Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis

SUPPLEMENTARY MATERIALS

**Supplementary Figure 1: Age distribution of patients ≥ 70 years of age with mCRC treated with or without bevacizumab.**

Progression free survival rates at 12 months

Overall survival rate at 12 months

Supplementary Figure 2: Funnel plots for progression-free survival (upper panel) and overall survival (lower panel) at 12 months showing there are no indications of selection bias.

Study	Events	Total		Proportion	95%-CI	W(random)
Treatment with antibodies						
Díaz-Rubio E. et al., 2012	4	70		0.06	[0.02; 0.14]	18.9%
Feliu J. et al, 2010	1	59		0.02	[0.00; 0.09]	12.7%
Okita N. et al, 2012	1	7		0.14	[0.00; 0.58]	11.9%
Souglakos J. et al, 2012	0	118		0.00	[0.00; 0.03]	8.9%
Tol J. et al, 2009	12	81		0.15	[0.08; 0.24]	21.2%
Random effects model		**335**		**0.06**	**[0.02; 0.15]**	**73.6%**
Heterogeneity: I-squared=67.4%, tau-squared=0.9255, p=0.0154						
Treatment without antibodies						
Arkenau H-T. et al, 2008	0	138		0.00	[0.00; 0.03]	8.9%
Borner M. et al, 2008	0	12		0.00	[0.00; 0.26]	8.7%
Koopmann M. et al, 2007	0	64		0.00	[0.00; 0.06]	8.9%
Random effects model		**214**		**0.01**	**[0.00; 0.05]**	**26.4%**
Heterogeneity: I-squared=0%, tau-squared=0, p=0.4789						
Random effects model		**549**		**0.03**	**[0.01; 0.09]**	**100%**
Heterogeneity: I-squared=66.9%, tau-squared=1.286, p=0.0036						
Test for subgroup differences: p=0.0766						

Proportion hypertonic events

Supplementary Figure 3: Effect of bevacizumab on the incidence of hypertension in patients ≥ 70 years of age with mCRC.

Supplementary Table 1: Multivariate cox regression analysis of various demographic and clinical characteristics on PFS and OS in in patients ≥ 70 years of age with mCRC

Variable	HR [95% CI]	*P*-value
PFS		
No monoclonal antibody use	1.40 [1.12–1.75]	0.0048
Age [per year]	1.03 [1.001–1.06]	0.0105
Neuropathy:		
Grade 0–2	Reference	
Grade 3	0.65 [0.47–0.91]	
Grade 4	1.00 [0.37–2.71]	0.0105
Dehydration:		
Grade 0–2	Reference	
Grade 3–4	3.00 [1.32–6.78]	0.0184
Bleeding grade 3-4	3.34 [1.36–8.21]	0.0199
Hand-foot syndrome:		
Grade 0–2	Reference	
Grade 3	0.64 [0.44–0.94]	0.0276
OS		
No monoclonal antibody use	1.41 [1.10–1.80]	0.0016
Age [per year]	1.06 [1.03–1.09]	< 0.0001
Bleeding grade 3-4	4.83 [1.85–12.65]	0.0012
Dyspnoea:		
Grade 0–2	Reference	
Grade 3	3.319 [1.12–9.84]	
Grade 4–5	6.17 [2.05–18.37]	0.0012
Dehydration:		
Grade 0–2	Reference	
Grade 3–4	1.70 [1.68–12.66]	0.0221
Neuropathy:		
Grade 0–2	Reference	
Grade 3	0.61 [0.42–0.88]	
Grade 4	0.99 [0.39–2.54]	0.0036
Fracture:		
Grade 0–2	Reference	
Grade 3	0.14 [0.02–1.07]	0.038
Cardiac events	1.56 [0.86–2.83]	0.0472